Back to Journals » Drug Design, Development and Therapy » Volume 13

Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

Authors Shu X, Chi L

Received 10 September 2018

Accepted for publication 22 January 2019

Published 13 May 2019 Volume 2019:13 Pages 1633—1641

DOI https://doi.org/10.2147/DDDT.S186992

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Professor Manfred Ogris


Xiangrong Shu,1 Liqun Chi2

1Department of Pharmacy, Tianjin Huanhu Hospital, Tianjin 300050, China; 2Department of Pharmacy, Haidian Maternal & Child Health Hospital of Beijing, Beijing 100080, China

Objective: Pravastatin has been suggested to increase circulating adiponectin in humans. However, results of randomized controlled trials (RCTs) are inconsistent. We aimed to systematically evaluate the influence of pravastatin on circulating adiponectin in humans by performing a meta-analysis of RCTs.
Materials and methods: Studies were identified via systematic searching of PubMed, Embase, and Cochrane’s Library databases. A random effect model was used to pool the results. Meta-regression and subgroup analyses were applied to explore the source of heterogeneity.
Results: Eight RCTs with nine comparisons of 595 participants were included. Pravastatin treatment was associated with a significant increased level of circulating adiponectin as compared with controls (weighted mean difference [WMD] =0.63 µg/mL; 95% CI, 0.17–1.09 µg/mL; P=0.007) with moderate heterogeneity (I2=28%). These results were confirmed by meta-analysis of double-blinded placebo-controlled RCTs (WMD =0.82 µg/mL; P=0.01). Meta-regression analyses indicated that proportions of males in each study were positively correlated with the effect of pravastatin on adiponectin (coefficient: 0.015, P=0.03). Subgroup analyses confirmed that pravastatin significantly increased adiponectin in studies of males (WMD =1.41 µg/mL; P=0.008), but not in those of females (WMD =-0.04 µg/mL; P=0.94).
Conclusion: Pravastatin treatment is associated with increased circulating adiponectin. Gender difference may exist regarding the effect of pravastatin treatment on adiponectin.

Keywords: pravastatin, adiponectin, meta-analysis, randomized controlled trials


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]